Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.48 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711945 | 0.93 | MAPKAPK2 (0.48) | MAPKAPK2MAP3K8ATM | |
| SCHEMBL4714778 | 0.90 | JAK1 (0.52) | MAPKAPK2MAP3K8ACVR1 | |
| SCHEMBL2247254 | 0.85 | MAP3K8 (0.54) | MAP3K8ACVR1ATM | |
| SCHEMBL4715165 | 0.83 | HTT (0.51) | MAPKAPK2MAP3K8 | |
| SCHEMBL4714182 | 0.80 | HTR7 (0.54) | MAP3K8ACVR1 | |
| SCHEMBL2038356 | 0.77 | MAP3K8 (0.50) | MAP3K8ACVR1 | |
| SCHEMBL5615107 | 0.77 | AKT1 (0.67) | MAP3K8ALK | |
| SCHEMBL4711426 | 0.76 | MAP3K8 (0.48) | MAP3K8ACVR1ATM | |
| SCHEMBL2034246 | 0.75 | MAP3K8 (0.50) | MAP3K8ATM | |
| SCHEMBL2036570 | 0.75 | MTOR (0.48) | MAP3K8ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| EP-1687305-B1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | claimed |
| JP-2007511575-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | claimed |
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1687305-B1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | ABL1, MAP4K2, MAP3K1 | MAPKAPK2 34/4885MAP4K1 8/4885MAP3K8 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.